US4966894A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Polysulfated heparins for treating diseases caused by retroviruses
Assignee: BASF SE
•
Filing: 1988-12-22
•
Granted: 1990-10-30
•
Expires: 2008-12-22
Abstract
Abstract Polysulfated heparins are used for the preparation of drugs for the prophylaxis and therapy of diseases caused by retroviruses.
Inventors
- 👤 Dieter Herr
- 👤 Thomas Doerper
- 👤 Lothar Daum
- 👤 Karl-Heinz Geiss
- 👤 Achim Moeller
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-09 17:06
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; A61P; A61P31/00; A61P31/12
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
59 words
A method of treating a disease caused by a retrovirus, which comprises administering a polysulfated heparin to a patient suffering from said disease in an amount effective for inhibiting replication of said retrovirus in said patient, said polysulfate heparin having a molecular weight in the range of about 2,000-20,000 and having a sulfur content from about 13.5 to 15%.
Claim 2
Independent Claim
59 words
A method of treating a disease caused by a retrovirus, which comprises administering a polysulfated heparin to a patient suffering from said disease in an amount effective for inhibiting replication of said retrovirus in said patient, said polysulfate heparin having a molecular weight in the range of about 2,000-20,000 and having a sulfur content from about 13.5 to 15%.
Claim 3
Dependent Claim
17 words
The method according to claim 1, wherein said polysulfated heparin has a molecular weight of from 2000-9000.
Claim 4
Dependent Claim
27 words
The method according to claim 1, wherein said polysulfated heparin is in the form of a free acid or in the form of salts with physiologically-acceptable bases.
Claim 5
Dependent Claim
32 words
The method according to claim 1, wherein said polysulfated heparin has a molecular weight in the range of 2,800 to 14,100, and a sulfur content in the range of 13.6 to 14.9%.
Claim 6
Dependent Claim
38 words
The method according to claim 1, wherein said polysulfated heparin is administered in an amount of about 10 to 1,000 mg/kg body weight for oral administration, and of about 0.1 to 10 mg/kg body weight for parenteral administration.
References Cited (Backward Citations)
EP0240098A2
Cited
EP0270317A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-10-29 | 1994-04-30 | 1994-10-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-10-29 | 1998-04-30 | 1998-10-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-10-29 | 2002-04-30 | 2002-10-30 | $7700.00 | Window Closed / Lapsed |